Literature DB >> 21686846

Acute fulminant carditis presenting with sustained ventricular tachycardia, and recovery after extracorporeal cardiopulmonary resuscitation.

Jen-Her Lu1, Renbing Tang, Shujen Chen, Hsiao-Huang Chang.   

Abstract

A 12-year-old boy consulted a local physician with complaints of cough, abdominal pain, shortness of breath and general malaise. Medications for symptomatic relief and bed rest were suggested. The flu-like symptoms were relieved on the 2nd day, and the general malaise with repeated vomiting, chest pain and chest tightness attenuated on the 3rd day. A chest x ray showed multiple pneumonic patches with borderline cardiomegaly. Poor left ventricular function was noted, and the left ventricular ejection fraction was reduced to 21%. Although multiple episodes of sustained ventricular tachycardia were converted by six repeated cardiac defibrillations and a xylocaine (intravenous) bolus infusion, his general condition went downhill to shock and proceeded to several episodes of heart standstill that necessitated cardiopulmonary resuscitation. Extracorporeal cardiopulmonary resuscitation was installed via femoral cannulation. Cardiac function progressively recovered to normal, and extracorporeal membrane oxygenation was removed on the 7th day. The patient completely recovered and was discharged on the 15th day with no neurological sequelae.

Entities:  

Year:  2009        PMID: 21686846      PMCID: PMC3029596          DOI: 10.1136/bcr.07.2008.0355

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Impact of multiple organ system dysfunction and nosocomial infections on survival of children treated with extracorporeal membrane oxygenation after heart surgery.

Authors:  V L Montgomery; J M Strotman; M P Ross
Journal:  Crit Care Med       Date:  2000-02       Impact factor: 7.598

2.  Duration of cardiopulmonary resuscitation before extracorporeal rescue: how long is not long enough?

Authors:  Robert B Kelly; Penny A Porter; Andreas H Meier; John L Myers; Neal J Thomas
Journal:  ASAIO J       Date:  2005 Sep-Oct       Impact factor: 2.872

3.  Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis.

Authors:  Yih-Sharng Chen; Jou-Wei Lin; Hsi-Yu Yu; Wen-Je Ko; Jih-Shuin Jerng; Wei-Tien Chang; Wen-Jone Chen; Shu-Chien Huang; Nai-Hsin Chi; Chih-Hsien Wang; Li-Chin Chen; Pi-Ru Tsai; Sheoi-Shen Wang; Juey-Jen Hwang; Fang-Yue Lin
Journal:  Lancet       Date:  2008-07-04       Impact factor: 79.321

4.  Therapeutic hypothermia after cardiac arrest.

Authors:  Arthur B Sanders
Journal:  Curr Opin Crit Care       Date:  2006-06       Impact factor: 3.687

5.  Child with fulminant myocarditis survived by ECMO Support--report of a child case.

Authors:  Makoto Taoka; Motomi Shiono; Mitsumasa Hata; Akira Sezai; Mitsuru Iida; Isamu Yoshitake; Shinji Wakui; Nanao Negishi; Yukiyasu Sezai; Kazutomo Minami
Journal:  Ann Thorac Cardiovasc Surg       Date:  2007-02       Impact factor: 1.520

6.  Survival outcomes after rescue extracorporeal cardiopulmonary resuscitation in pediatric patients with refractory cardiac arrest.

Authors:  Bahaaldin Alsoufi; Osman O Al-Radi; Rakan I Nazer; Colleen Gruenwald; Celeste Foreman; William G Williams; John G Coles; Christopher A Caldarone; Desmond G Bohn; Glen S Van Arsdell
Journal:  J Thorac Cardiovasc Surg       Date:  2007-10       Impact factor: 5.209

7.  Idioventricular rhythm induced by therapeutic hypothermia.

Authors:  En-Ting Wu; Shu-Chien Huang; Nai-Hsin Chi; Ming-Tai Lin; Wen-Je Ko; Shoei-Shen Wang; Jou-Kou Wang; Mei-Hwan Wu
Journal:  Resuscitation       Date:  2007-11-01       Impact factor: 5.262

8.  Acute-onset dysrhythmia heralding fulminant myocarditis and refractory cardiac arrest treated with ED cardiopulmonary bypass and extracorporeal membrane oxygenation.

Authors:  Loren G Yamamoto; Lynette L Young
Journal:  Am J Emerg Med       Date:  2007-03       Impact factor: 2.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.